Cancer & SURVIVEiT News

The SURVIVEiT® NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

medpage

‘Shared Decision-Making’: Real or Just a Feel-Good Buzzword?

'Shared Decision-Making': Real or Just a Feel-Good Buzzword? by Howard Wolinsky, Contributing Writer, MedPage Today November 04, 2018 "Henry" had seen his new university-based family doctor, whom he referred to as Doogie Howser,...
New_FDA_Approval!

FDA Approves Lorlatinib for ALK+ NSCLC

FDA Approves Lorlatinib for ALK+ NSCLC Jason M. Broderick @jasoncology Published: Friday, Nov 02, 2018 The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small...
Executive_Director_(1)

SURVIVEIT® NAMES EXECUTIVE DIRECTOR JOY BREWSTER RUSTHOVEN TO LEAD PATIENT ADVOCACY NONPROFIT

FOR IMMEDIATE RELEASE CONTACT: info@surviveit.org SURVIVEIT® NAMES EXECUTIVE DIRECTOR JOY BREWSTER RUSTHOVEN TO LEAD PATIENT ADVOCACY NONPROFIT SIOUX FALLS, SD. (Oct. 31, 2018) SURVIVEiT® announced Joy Brewster Rusthoven has been named...
New_FDA_Approval!

FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer

FDA approves talazoparib for gBRCAm HER2-negative locally advanced or metastatic breast cancer​ On October 16, 2018, the Food and Drug Administration approved talazoparib (TALZENNA, Pfizer Inc.), a poly (ADP-ribose) polymerase...
New_FDA_Approval!

FDA approves Copiktra for leukemia, lymphoma subtypes

FDA approves Copiktra for leukemia, lymphoma subtypes September 25, 2018 The FDA approved duvelisib for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...
New_FDA_Approval!

FDA approves first treatment for advanced form of the second most common skin cancer

FDA approves first treatment for advanced form of the second most common skin cancer New drug targets PD-1 pathway The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection...
Progress!_

Rucaparib Granted Breakthrough Designation by FDA for mCRPC

Rucaparib Granted Breakthrough Designation by FDA for mCRPC Ariela Katz Published Online:5:05 PM, Tue October 2, 2018 Rucaparib (Rubraca) has received a breakthrough therapy designation from the FDA for single-agent use...
New_FDA_Approval!

FDA approves dacomitinib for metastatic non-small cell lung cancer

FDA approves dacomitinib for metastatic non-small cell lung cancer On Sept. 27, 2018, the Food and Drug Administration approved dacomitinib tablets (VIZIMPRO, Pfizer Pharmaceutical Company) for the first-line treatment of...
Progress!_

First-line brigatinib improves PFS for ALK-positive non-small cell lung cancer

First-line brigatinib improves PFS for ALK-positive non-small cell lung cancer September 27, 2018 First-line therapy with brigatinib significantly improved PFS compared with crizotinib among treatment-naive patients with advanced ALK-positive non-small cell lung...
Progress!_

World Lung 2018 – Alunbrig squares up to Xalkori, but the field is getting crowded

World Lung 2018 – Alunbrig squares up to Xalkori, but the field is getting crowded by Jacob Plieth Takeda's drug leads the charge of small-molecule tyrosine kinase inhibitors, some of...
mammogram-breast-cancer

Study shows value of breast cancer patients seeking second opinions

Study shows value of breast cancer patients seeking second opinions As scary as a cancer diagnosis can be, pausing to get more information can yield benefits Dawn Brazell | brazell@musc.edu | September 19,...
83_ellefson

Cancer Doesn’t Frighten Me

Cancer Doesn’t Frighten Me Living with advanced-stage lung cancer awakened me to live my best life. By Matt Ellefson, as told to Jo Cavallo September 25, 2018 In the fall...